Present and evolving role of eptifibatide in the treatment of acute coronary syndromes

References

• Braunwald E. Unstable angina: an etiologic approach to management. Circulation98(21), 2219–2222 (1998).
   PubMed Web of Science ®Google Scholar
• Harker LA. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am. J. Cardiol.60(3), 20B–28B (1987).
   PubMed Web of Science ®Google Scholar
• The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N. Engl. J. Med.339(7), 436–443 (1998).
   PubMed Web of Science ®Google Scholar
• A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N. Engl. J. Med.338(21), 1498–1505 (1998).
   PubMed Web of Science ®Google Scholar
• Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N. Engl. J. Med.338(21), 1488–1497 (1998).
   PubMed Web of Science ®Google Scholar
• Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation105(3), 316–321 (2002).
   PubMed Web of Science ®Google Scholar
• Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet357(9272), 1915–1924 (2001).
   PubMed Web of Science ®Google Scholar
• Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N. Engl. J. Med.330(14), 956–961 (1994).
   PubMed Web of Science ®Google Scholar
• Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet349(9063), 1429–1435 (1997).
   PubMed Web of Science ®Google Scholar
• Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N. Engl. J. Med.336(24), 1689–1696 (1997).
   PubMed Web of Science ®Google Scholar
• Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet352(9122), 87–92 (1998).
   PubMed Web of Science ®Google Scholar
• Scarborough RM. Development of eptifibatide. Am. Heart J.138(6 Pt 1), 1093–1104 (1999).
   PubMed Web of Science ®Google Scholar
• Harrington RA, Kleiman NS, Kottke-Marchant K et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am. J. Cardiol.76(17), 1222–1227 (1995).
   PubMed Web of Science ®Google Scholar
• Schror K, Weber AA. Comparative pharmacology of GP IIb/IIIa antagonists. J. Thromb. Thrombolysis15(2), 71–80 (2003).
   PubMed Web of Science ®Google Scholar
• Tcheng JE, Talley JD, O’Shea JC et al. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Am. J. Cardiol.88(10), 1097–1102 (2001).
   PubMed Web of Science ®Google Scholar
• Phillips DR, Teng W, Arfsten A et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation96(5), 1488–1494 (1997).
   PubMed Web of Science ®Google Scholar
• Tardiff BE, Jennings LK, Harrington RA et al. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT. Circulation104(4), 399–405 (2001).
   PubMed Web of Science ®Google Scholar
• Gilchrist IC, O’Shea JC, Kosoglou T et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation104(4), 406–411 (2001).
   PubMed Web of Science ®Google Scholar
• Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet356(9247), 2037–2044 (2000).
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Newby LK, Harrington RA et al. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome – study design and rationale. Am. Heart J.149(6), 994–1002 (2005).
   PubMed Web of Science ®Google Scholar
• Gretler DD. Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin. Clin. Ther.25(10), 2564–2574 (2003).
   PubMed Web of Science ®Google Scholar
• Gretler DD, Guerciolini R, Williams PJ. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. Clin. Ther.26(3), 390–398 (2004).
   PubMed Web of Science ®Google Scholar
• Batchelor WB, Tolleson TR, Huang Y et al. Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation106(12), 1470–1476 (2002).
   PubMed Web of Science ®Google Scholar
• The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation96(5), 1445–1453 (1997).
   PubMed Web of Science ®Google Scholar
• Danzi GB, Capuano C, Sesana M, Mauri L, Sozzi FB. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention. Am. J. Cardiol.97(4), 489–493 (2006).
   PubMed Web of Science ®Google Scholar
• Dalby M, Montalescot G, Bal dit Sollier C et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J. Am. Coll. Cardiol.43(2), 162–168 (2004).
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Schuhlen H et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N. Engl. J. Med.350(3), 232–238 (2004).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of platelets (CLEAR PLATELETS) study. Circulation111(9), 1153–1159 (2005).
   PubMed Web of Science ®Google Scholar
• Kleiman NS, Lincoff AM, Flaker GC et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation101(7), 751–757 (2000).
   PubMed Web of Science ®Google Scholar
• Boersma E, Harrington RA, Moliterno DJ et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet359(9302), 189–198 (2002).
   PubMed Web of Science ®Google Scholar
• Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur. Heart J.23(18), 1441–1448 (2002).
   PubMed Web of Science ®Google Scholar
• Marso SP, Bhatt DL, Roe MT et al. Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. Circulation102(24), 2952–2958 (2000).
   PubMed Web of Science ®Google Scholar
• Dyke CM, Bhatia D, Lorenz TJ et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Ann. Thorac. Surg.70(3), 866–871 (2000).
   PubMed Web of Science ®Google Scholar
• Greenbaum AB, Harrington RA, Hudson MP et al. Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. J. Am. Coll. Cardiol.37(2), 492–498 (2001).
   PubMed Web of Science ®Google Scholar
• Lauer MA, Houghtaling PL, Peterson JG et al. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation104(23), 2772–2777 (2001).
   PubMed Web of Science ®Google Scholar
• Braunwald E, Antman EM, Beasley JW et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction – summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J. Am. Coll. Cardiol.40(7), 1366–1374 (2002).
   PubMed Web of Science ®Google Scholar
• Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation104(23), 2767–2771 (2001).
   PubMed Web of Science ®Google Scholar
• Mark DB, Harrington RA, Lincoff AM et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation101(4), 366–371 (2000).
   PubMed Web of Science ®Google Scholar
• Brown RE, Henderson RA, Koster D, Hutton J, Simoons ML. Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in Unstable angina: Receptor Suppression Using Integrilin Therapy. Eur. Heart J.23(1), 50–58 (2002).
   PubMed Web of Science ®Google Scholar
• Brown R, Armstrong P. Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis. Can. J. Cardiol.19(2), 161–166 (2003).
   PubMed Web of Science ®Google Scholar
• Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet349(9063), 1422–1428 (1997).
   PubMed Web of Science ®Google Scholar
• Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial. Am. Heart J.141(3), 402–409 (2001).
   PubMed Web of Science ®Google Scholar
• Schweiger MJ, Changezi HU, Naglieri-Prescod D, Cook JR. Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention. Clin. Ther.25(1), 225–234 (2003).
   PubMed Web of Science ®Google Scholar
• Suleiman M, Gruberg L, Hammerman H et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention. J. Invasive Cardiol.15(6), 319–323 (2003).
   PubMedGoogle Scholar
• Bittl JA, Strony J, Brinker JA et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N. Engl. J. Med.333(12), 764–769 (1995).
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Bittl JA, Harrington RA et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA289(7), 853–863 (2003).
   PubMed Web of Science ®Google Scholar
• Gibson CM, Morrow DA, Murphy SA et al. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J. Am. Coll. Cardiol.47(12), 2364–2373 (2006).
   PubMed Web of Science ®Google Scholar
• Stone GW, McLaurin BT, Cox DA et al. Bivalirudin for patients with acute coronary syndromes. N. Engl. J. Med.355(21), 2203–2216 (2006).
   PubMed Web of Science ®Google Scholar
• The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med.354(14), 1464–1476 (2006).
   PubMed Web of Science ®Google Scholar
• Stone GW, Bertrand ME, Moses JW et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA297(6), 591–602 (2007).
   Google Scholar
• Rao SV, O’Grady K, Pieper KS et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am. J. Cardiol.96(9), 1200–1206 (2005).
   PubMed Web of Science ®Google Scholar
• Rao SV, Jollis JG, Harrington RA et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA292(13), 1555–1562 (2004).
   PubMed Web of Science ®Google Scholar
• Alexander KP, Chen AY, Roe MT et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA294(24), 3108–3116 (2005).
   PubMed Web of Science ®Google Scholar
• Alexander KP, Chen AY, Newby LK et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) initiative. Circulation114(13), 1380–1387 (2006).
   PubMed Web of Science ®Google Scholar
• Kirtane AJ, Piazza G, Murphy SA et al. Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. J. Am. Coll. Cardiol.47(12), 2374–2379 (2006).
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Neumann F-J et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA295(13), 1531–1538 (2006).
   PubMed Web of Science ®Google Scholar
• Newby LK, Ohman EM, Christenson RH et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation103(24), 2891–2896 (2001).
   PubMed Web of Science ®Google Scholar